Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aura Biosciences, Inc. - Common Stock (NQ: AURA )

7.500 +0.220 (+3.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 120,464
Open 7.300
Bid (Size) 7.130 (1)
Ask (Size) 7.900 (1)
Prev. Close 7.280
Today's Range 7.300 - 7.655
52wk Range 6.630 - 12.38
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease
Aura Biosciences released early Phase 1 trial data on bel-sar for non-muscle-invasive bladder cancer, showing promising clinical activity and a favorable safety profile. 
Via Benzinga

Performance

YTD
-9.20%
-9.20%
1 Month
-6.13%
-6.13%
3 Month
-16.67%
-16.67%
6 Month
-2.98%
-2.98%
1 Year
-14.19%
-14.19%

More News

Read More
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Recap: Aura Biosciences Q4 Earnings
Via Benzinga
3 Small-Cap Stocks Ready to Deliver Significant Growth
Via MarketBeat
Topics Economy
Exposures Interest Rates
Aura Biosciences Touts Promising Data From Eye Cancer Candidate
Via Benzinga
AURA Stock Earnings: Aura Biosciences Beats EPS for Q2 2024
Via InvestorPlace
AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024
Via InvestorPlace
AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023
Via InvestorPlace
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
From Aura Biosciences Inc.
Via Business Wire
Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
Why Aura Biosciences Stock Hit A New 52-Week Low Today
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Aura Biosciences Announces Pricing of Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.